Advertisement

Topics

LabCorp to Acquire Specialty CRO Chiltern for $1.2 Billion in Cash

13:35 EDT 31 Jul 2017 | Speciality Pharma Journal

BURLINGTON, N.C. & WILMINGTON, N.C. & LONDON–(BUSINESS WIRE)–LabCorp® (NYSE:LH), a leading global life sciences company, and Chiltern, a specialty CRO, announced today that LabCorp will acquire Chiltern pursuant to a definitive agreement with Chiltern’s shareholders in an all-cash transaction valued at approximately $1.2 billion. Once the transaction is complete, Chiltern will become part of LabCorp’s …

Original Article: LabCorp to Acquire Specialty CRO Chiltern for $1.2 Billion in Cash

NEXT ARTICLE

More From BioPortfolio on "LabCorp to Acquire Specialty CRO Chiltern for $1.2 Billion in Cash"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...